Pfizer has announced it's trialing a third COVID-19 shot to be administered six to 12 months after a patient's two-dose regimen. The trial will examine whether a booster shot of the Pfizer-BioNTech would tackle any new strains that emerge, the two companies said Thursday.
The study will use participants from its Phase 1 trial in the US "in order to be prepared for any potential future strain changes."
Pfizer said it hasn't seen any evidence that its current vaccine fails to protect against newvariants. The trial is simply to be prepared in case a strain becomes resistant to the vaccine.
"The flexibility of our proprietary mRNA vaccine platform allows us to technically develop booster vaccines within weeks, if needed," said Ugur Sahin, BioNTech CEO, in a statement. "We take these steps in order to ensure a long-term immunity against the virus and its variants."
Earlier this month, President Joe Biden announced that the US is buyingto cover 300 million people in the country by the end of July -- though this doesn't mean everyone will be vaccinated by then.
"We've now purchased enough vaccine supply to vaccinate all Americans," Biden said. Actually administering the vaccines to all Americans could take longer because vaccinations are managed at a state and local level.
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.